Vernakalant is a new antiarrhythmic drug that acts selectively in the atrium, targeting atrial specific channels. Vernakalant is an anti-arrhythmic medicine that acts preferentially in the atria by prolonging atrial refractoriness and by rate-dependently slowing impulse conduction. These anti-fibrillatory actions on refractoriness and conduction are thought to suppress reentry, and are potentiated in the atria during atrial fibrillation. The preferential effects of vernakalant on the atria are postulated to result from its block of currents that are expressed in the atria (e.g., the ultra-rapid delayed rectifier potassium current; and the acetylcholine-activated potassium current), but not in the ventricles, as well as the unique electrophysiologic condition of the fibrillating atria. An oral formulation of vernakalant is in phase II development as a long-term maintenance therapy for patients with atrial fibrillation. An intravenous formulation of vernakalant has been launched in most countries in Europe and Latin America, and in Hong Kong, for the acute conversion of atrial fibrillation. The product has been approved for the acute conversion of atrial fibrillation in South Africa, Iceland, Turkey and is awaiting approval for the same indication in Canada. Phase III development of the IV formulation is ongoing at sites in Asia, and development is currently on hold in the US.

Cibenzoline is a class I sodium channel blocker antiarrhythmic drug available in a limited number of countries. Cibenzoline also has moderate calcium channel blocking (class IV) effects and prolongs the action potential duration through its potassium channel blocking (class III) effect. It is used for the treatment of supraventricular and ventricular arrhythmias, and in obstructive hypertrophic cardiomyopathy.

Fluocortolone is a topical corticosteroid (class of steroid hormones formed in the adrenal gland). Is primary indicated in condition like, Ana fissure, Dermatosis haemorrhoids, proctitis. The signs and symptoms that are produced after the acute overdosage include convulsions, respiratory arrest, allergic skin reactions. Glucocorticoids, such as fluocortolone, act through nuclear hormone receptors Schaaf and Cidlowski (2002). The two members of this family are glucocorticoid receptor (GR) type I and GR type I I. Activation of these sites alters gene expression of endogenous agents that influence immune and inflammatory responses.

Xipamide is a diuretic of thiazide class. It is used for the treatment of hypertension and edema. The diuretic effect of the drug is due to reduction of sodium reabsorption and increase in potassium excretion.

Meglutol (3-Hydroxy-3-methylglutaric acid, HMGA) is an antilipemic agent which lowers cholesterol, triglycerides, serum beta-lipoproteins and phospholipids, and inhibits the activity of hydroxymethylglutarryl CoA reductases, which is the rate-limiting enzyme in the biosynthesis of cholesterol. 3-Hydroxy-3-methylglutaric acid (HMGA) is a competitive inhibitor of 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCoAR) and strongly reduces cholesterol biosynthesis both in vitro and in vivo. In hamster model HMGA is effective in reducing both bile cholesterol supersaturation and hypercholesterolemia.

Nicofuranose is a niacin derivative used as a hypolipidemic agent. The Nicofuranose administration leads to inhibition of free fatty acid turnover and consequently a marked reduction in triglyceride turnover. Nicofuranose, unlike clofibrate, did not affect the mechanisms responsible for the clearance of plasma triglycerides.

Proscillaridin is a substance that was used in Europe for the treatment of heart failure and atrial fibrillation. Proscillaridin belongs to glycosides and acts as a Na /K -ATPase inhibitor.

MUZOLIMINE, a dichlorobenzene derivative, is a loop diuretic with slow effect and long lasting action. It was used for the treatment of hypertension but was withdrawn from the market because of severe neurological effects.

Nilvadipine (NIVADIL®) is a L-type calcium channel blocker for treatment of hypertension. It inhibits the influx of extracellular calcium through myocardial and vascular membrane pores by physically plugging the channel. The decrease in intracellular calcium inhibits the contractile processes of smooth muscle cells, causing dilation of the coronary and systemic arteries, increased oxygen delivery to the myocardial tissue, decreased total peripheral resistance, decreased systemic blood pressure, and decreased afterload.